Marie E. Steiner, M.D vigora 100 ., Paul M. Ness, M.D., Susan F. Assmann, Ph.D., Darrell J. Triulzi, M.D., Steven R. Sloan, M.D., Ph.D., Meghan Delaney, D.O., M.P.H., Suzanne Granger, M.S., Elliott Bennett-Guerrero, M.D., Morris A. Blajchman, M.D., Vincent Scavo, M.D., Jeffrey L. Carson, M.D., Jerrold H. Levy, M.D., Glenn Whitman, M.D.N., Shelley Pulkrabek, M.T., C.C.R.C., Thomas L. Ortel, M.D., Ph.D., Larissa Bornikova, M.D., Thomas Raife, M.D., Kathleen E. Puca, M.D., Richard M. Kaufman, M.D., Gregory A. Nuttall, M.D., Pampee P. Adolescent, M.D., Ph.D., Samuel Youssef, M.D., Richard Engelman, M.D., Philip E. Greilich, M.D., Ronald Miles, M.D., Cassandra D.
Interpretation of the imaging was performed at an exterior core laboratory by staff who were unacquainted with the treatment-group assignments , medical data, and outcomes. External, independent clinical monitors validated the clinical data. Statistical Analysis The trial was powered to detect a shift in the distribution of scores on the modified Rankin scale at 90 days between the intervention and control groups, with scores of 5 and 6 combined, with the assumption that the differential effect would lead to a common odds ratio of just one 1.8. A total required sample of 500 participants was anticipated.